

The textbook on lung cancer: time for personalized medicine

Editorial Office, Journal of Thoracic Disease, Guangzhou 510120, China

Correspondence to: Editorial Office, Journal of Thoracic Disease, Guangzhou 510120, China. Email: jtd@amepc.org.

Submitted Mar 31, 2015. Accepted for publication Apr 02, 2015.

doi: 10.3978/j.issn.2072-1439.2015.04.43

View this article at: <http://dx.doi.org/10.3978/j.issn.2072-1439.2015.04.43>

We are glad to announce that the book Lung Cancer is officially published by the AME Publishing Company (Figure 1).

At the 3rd Asian Single Port VATS Symposium & Live Surgery held on March 26-27 in Hong Kong, an announcement ceremony for the book on Lung Cancer was held (Figure 2). In its debut, we are glad to see the book well received by the international experts.

Our Honorary Editors-in Chief for Lung Cancer are Prof. Jie He and Prof. Rafael Rosell and the Editors-in Chief are Prof. Jianxing He, Prof. Thomas A. D'Amico and Prof. Xiuyi Zhi. The Associate Editors-in Chief include Prof. Qun Wang, Prof. Tristan D. Yan, Prof. Calvin Ng, Prof. Caicun Zhou, Prof. Heather A. Wakelee, Dr. Wenhua Liang.

Despite many years of dedicated effort, including basic, translational and clinical research, public education, and health care policy, lung cancer remains the number one cause of death by malignancy in the world, and it is responsible for as many deaths as colon, breast, pancreas and prostate cancers combined in the US. Thus, successful efforts to better understand and better treat lung cancer will have long lasting ramifications, for patient care specifically and for public health globally, as well.

The volume, Lung Cancer, is just such an effort. Comprised of contributions by the most accomplished scientists and clinicians internationally, Lung Cancer thoroughly examines the spectrum of topics related to better understanding and better treating the world's most lethal malignancy.

From the basic science of lung cancer to the most advanced therapeutic techniques, this text provides the reader—student or professional—with a most



Figure 1 The book Lung Cancer is launched by the AME Publishing Company.

comprehensive analysis. Lung Cancer also provides practical information epitomizing the rapid progress in the field of lung cancer today and instilling in physicians the confidence derived from this knowledge when dealing with patients.

We would like to express our gratitude to all the leading investigators who have contributed to this endeavor and to the growing knowledge of lung cancer today.

The book Lung Cancer is now available both online and in print with English and Chinese version. Please enjoy.



Figure 2 The book on lung cancer was launched in the 3rd Asian Single Port VATS Symposium & Live Surgery with the recognition of the world known experts (from right to left): Prof. Alan Sihoe; Prof. Jianxing He; Prof. Jheon Sanghoon; Prof. Thomas D'Amico; Prof. Calvin Ng; Prof. Keneng Chen.

Catalogue of Lung Cancer:

Pathology

- 1 **Molecular biology of lung cancer**
Wendy A. Cooper, David C. L. Lam, Sandra A. O'Toole, John D. Minna
- 16 **The pivotal role of pathology in the management of lung cancer**
Morgan R. Davidson, Adi F. Gazdar, Belinda E. Clarke
- 34 **Towards optimal pathologic staging of resectable non-small cell lung cancer**
Raymond U. Osarogiagbon, Gail E. Darling
- 42 **Molecular determinants of lung cancer metastasis to the central nervous system**
Timothy G. Whitsett, Landon J. Inge, Harshil D. Dbruv, Philip Y. Cheung, Glen J. Weiss, Ross M. Bremner, Jeffrey A. Winkles, Nhan L. Tran
- 53 **Genetic susceptibility to lung cancer and co-morbidities**
Ian A. Yang, John W. Holloway, Kwun M. Fong
- 64 **Non-neuronal cholinergic system in airways and lung cancer susceptibility**
Laura Saracino, Michele Zorzetto, Simona Inghilleri, Ernesto Pozzi, Giulia Maria Stella

Diagnosis

- 75 **Diagnostic bronchoscopy—current and future perspectives**
Steven Leong, Tawimas Shaipanich, Stephen Lam, Kazuhiro Yasufuku
- 90 **Modern diagnostic and therapeutic interventional radiology in lung cancer**
Wai-Kit Lee, Eddie W. F. Lau, Kwang Chin, Oliver Sedlacek, Karin Steinke
- 105 **Screening for lung cancer with low-dose computed tomography: a review of current status**
Henry M. Marshall, Rayleen V. Bowman, Ian A. Yang, Kwun M. Fong, Christine D. Berg
- 125 **Exhaled breath analysis for lung cancer**
Annette G. Dent, Tom G. Sutedia, Paul V. Zimmerman
- 138 **Interventional pulmonology approaches in the diagnosis and treatment of early stage non small cell lung cancer**
Ryu Peter Hambrook Tofts, Peter M. J. Lee, Arthur Wai Sung
- 154 **Post-therapeutic positron emission tomography/computed tomography for early detection of non-small cell lung cancer recurrence**
Sonja Sudarski, Thomas Henzler, Stefan O. Schoenberg

- 163 **New TNM classification: achievements and hurdles**
Peter Goldstraw

Treatment

- 172 **A review of clinical practice guidelines for lung cancer**
Jutta J. von Dincklage, David Ball, Gerard A. Silvestri
- 190 **Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC)**
Jia Wei, Teresa Moran, Zhengyun Zou, Xiaoping Qian, Lifeng Wang, Carlos Camps, Wenjing Hu, Imane Chaib, Belén Sanchez, Lixia Xu, Niki Karachaliou, María Sanchez-Ronco, Baorui Liu, Rafael Rosell
- 199 **Management of elderly patients**
Alain Vergnenegre, Romain Corre, Hervé Lena, Hervé LeCaer
- 207 **Alternative to surgery in early stage NSCLC—interventional radiologic approaches**
Kyungmouk Steve Lee, Bradley B. Pua
- 221 **Supportive and palliative care for lung cancer patients**
Patsy Yates, Penelope Schofield, Isabella Zhao, David Currow

Surgery

- 227 **Thoracoscopic sleeve resection—the better approach?**
Calvin S.H. Ng
- 230 **Surgery in 2013 and beyond**
Rishendran Naidoo, Morgan N. Windsor, Peter Goldstraw
- 246 **Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?**
Yoshibisa Kobayashi, Tetsuya Mitsudomi
- 256 **Video-assisted thoracoscopic lobectomy—from an experimental therapy to the standard of care**
Tristan D. Yan
- 258 **Techniques of VATS lobectomy**
John D. Mitchell
- 263 **Contraindications of video-assisted thoracoscopic surgical lobectomy and determinants of conversion to open**
Jennifer M. Hanna, Mark F. Berry, Thomas A. D'Amico

- 272 **Current costs of video-assisted thoracic surgery (VATS) lobectomy**
Tunc Lacin, Scott Swanson

- 276 **Indication for VATS sublobar resections in early lung cancer**
Antonio E. Martin-Ucar, Maria Delgado Roel
- 283 **Totally thoracoscopic pulmonary anatomic segmentectomies: technical considerations**
Dominique Gossot, Rym Zaimi, Ludovic Fournel, Madalina Grigoriu, Emmanuel Brian, Charles Neveu
- 291 **Teaching video-assisted thoracic surgery (VATS) lobectomy**
Philip W. Carrott Jr, David R. Jones
- 297 **Right, middle, and lower bronchial sleeve lobectomy by video assisted thoracic surgery**
Xin Zhang, Gui-Lin Peng, Li-Xia Liang, Jian-Xing He
- 300 **Non-intubated complete thoracoscopic bronchial sleeve resection for central lung cancer**
Wenlong Shao, Kevin Phan, Xiaotong Guo, Jun Liu, Qinglong Dong, Jianxing He
- 304 **Anesthesia with nontracheal intubation in thoracic surgery**
Qinglong Dong, Lixia Liang, Yingfen Li, Jun Liu, Weiqiang Yin, Hanzhang Chen, Xin Xu, Wenlong Shao, Jianxing He
- 310 **Video-assisted thoracoscopic lobectomy for non-small cell lung cancer in patients with severe chronic obstructive pulmonary disease**
Wei Wang, Zhiqiang Xu, Xinguo Xiong, Weiqiang Yin, Xin Xu, Wenlong Shao, Hanzhang Chen, Jianxing He
- 318 **Analysis of feasibility and safety of complete video-assisted thoracoscopic resection of anatomic pulmonary segments under non-intubated anesthesia**
Zhibua Guo, Wenlong Shao, Weiqiang Yin, Hanzhang Chen, Xin Zhang, Qinglong Dong, Lixia Liang, Wei Wang, Guilin Peng, Jianxing He
- 326 **Comparative study of systematic thoracoscopic lymphadenectomy and conventional thoracotomy in resectable non-small cell lung cancer**
Wei Wang, Weiqiang Yin, Wenlong Shao, Gening Jiang, Qun Wang, Lunxu Liu, Deruo Liu, Zhen Wang, Zhibua Zbu, Hanzhang Chen, Jianxing He

Medical Oncology

- 333 **Neoadjuvant chemotherapy in early-stage non-small cell lung cancer**
Francesc Salvà, Enriqueta Felip
- 338 **Adjuvant chemotherapy of completely resected early stage nonsmall cell lung cancer (NSCLC)**
Ying Liang, Heather A. Wakelee
- 346 **VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer**
Xiuyi Zhi, Wen Gao, Baobui Han, Yue Yang, Hui Li, Deruo Liu, Changli Wang, Gong Min, Hao Long, James R. Rigas, Mark Carey, Thierry Jaban, Amanda Sammann, Joseph Reza, Daoyuan Wang, Michael J. Mann, David M. Jablons, Jianxing He, for the China Clinical Trials Consortium
- 353 **Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy**
Charles A. Butts
- 361 **Adjuvant molecularly targeted therapy—epidermal growth factor tyrosine kinase inhibition and beyond**
Joel W. Neal, Lecia V. Sequist
- 365 **The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era**
Zarnie Lwin, Jonathan W. Riess, David Gandara
- 375 **Chemotherapy advances in small-cell lung cancer**
Bryan A. Chan, Jermaine I. G. Coward
- 391 **Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer**
Peter Savas, Brett Hughes, Benjamin Solomon
- 408 **Apoptotic agents**
Dean A. Fennell
- 414 **Adaptive resistance to targeted therapies in cancer**
Rafael Rosell, Niki Karachaliou, Daniela Morales-Espinosa, Carlota Costa, Miguel Angel Molina, Irene Sansano, Amaya Gasco, Santiago Viteri, Bartomeu Massuti, Jia Wei, María González Cao, Alejandro Martínez Bueno
- 433 **Recent advances in radiotherapy for thoracic tumours**
Michael Fay, Christopher M. Poole, Gary Pratt
- 439 **Alternatives to surgery in early stage disease—stereotactic body radiotherapy**
Meredith Elana Giuliani, Andrea Bezjak
- 447 **Post-operative radiation therapy**
Amaury Paumier, Cécile Le Péchoux
- 457 **Proton radiotherapy in the treatment of lung cancer**
Heath Devin Skinner, Ritsuko Komaki

Prognosis

- 464 **Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures**
Simona Carnio, Silvia Novello, Mauro Papotti, MarcoLoiacono, Giorgio Vittorio Scagliotti
- 474 **Prognostic and predictive biomarkers in early stage NSCLC: CTCsand serum/plasma markers**
Philip A. J. Crosbie, Rajesh Shah, Yvonne Summers, Caroline Dive, Fiona Blackball
- 490 **Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung**
Pedro Mendez, Jose Luis Ramirez
- 501 **Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC)**
Laura Bonanno
- 513 **Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?**
Bartomeu Massuti, Jose Miguel Sanchez, Florentino Hernando-Trancho, Niki Karachaliou, Rafael Rosell
- 527 **Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients**
Margarita Majem, Jordi Remon
- 539 **EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data**
Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner

Radiotherapy

- 422 **State of the art of radiotherapy**
Pilar Garrido, M^a Eugenia Olmedo

- 544 **International trial of adjuvant therapy in high risk stage I nonsquamous cell carcinoma identified by a 14-gene prognostic signature**

Jobannes R. Kratz, Michael J. Mann, David M. Jablons

- 548 **Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis**

Wenhua Liang, Yaxiong Zhang, Shiyang Kang, Hui Pan, Wenlong Shao, Qiubua Deng, Xiaosbun Shi, Wei Wang, Jianxing He

Translational medicine

- 560 **FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications**

Hans-Ulrich Schildhaus, Lucia Nogova, Jürgen Wolf, Reinhard Buettner

- 569 **ALK and ROS1 as a joint target for the treatment of lung cancer: a review**

Raimon Puig de la Bellacasa, Niki Karachaliou, Roger Estrada-Tejedor, Jordi Teixidó, Carlota Costa, José I. Borrell

- 584 **Activated RET and ROS: two new driver mutations in lung adenocarcinoma**

Marc Bos, Masyar Gardizi, Hans-Ulrich Schildhaus, Reinhard Buettner, Juergen Wolf

- 594 **HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches**

Ana Christina Garrido-Castro, Enriqueta Felip

- 600 **Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)**

Teresa Morán, Vanesa Quiroga, María de los Llanos Gil, Laia Vilà, Nuria Pardo, Enric Carcereny, Laia Capdevila, Ana M. Muñoz-Mármol, Rafael Rosell

- 614 **KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach**

Javier de Castro Carpeño, Cristóbal Belda-Iniesta

- 624 **The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung**

Niki Karachaliou, Rafael Rosell, Santiago Viteri

- 632 **Inhibition of insulin-like growth factor receptor: end of atargeted therapy?**

Ratbi N. Pillai, Suresh S. Ramalingam

- 641 **MET inhibition in lung cancer**

Jessica Menis, Matteo Giaj Levra, Silvia Novello

- 658 **Irreversible EGFR-TKIs: dreaming perfection**

Lorenza Landi, Federico Cappuzzo

The book could now be viewed at: <http://www.jthoracdis.com/public/system/jtd/lung-cancer.pdf>

Acknowledgements

Disclosure: The author declares no conflict of interest.

Cite this article as: Editorial Office. The textbook on lung cancer: time for personalized medicine. J Thorac Dis 2015;7(4):E107-E111. doi: 10.3978/j.issn.2072-1439.2015.04.43